Post by miamianne67 on Jan 23, 2024 21:49:12 GMT
Shares of GILD plunged 10% Monday when it's Trodelvy trial aimed at small cell lung cancer failed to improve overall patient survival, reports the WSJ.
While there was a three month survival rate increase in median overall survival, the results didn't meeting the PH 3 primary endpoint.
Trodelvy is a new class of chemo known as "anti body drug conjugates" which target the agent at a tumor to reduce systemic side effects.
GILD has plans, though, saying it will explore how Trodelvy may help patients and to discuss the study with regulators.
So they aren't giving up, they have a plan and are going to try to implement it.....and are speaking about it. Refreshing.
While there was a three month survival rate increase in median overall survival, the results didn't meeting the PH 3 primary endpoint.
Trodelvy is a new class of chemo known as "anti body drug conjugates" which target the agent at a tumor to reduce systemic side effects.
GILD has plans, though, saying it will explore how Trodelvy may help patients and to discuss the study with regulators.
So they aren't giving up, they have a plan and are going to try to implement it.....and are speaking about it. Refreshing.